A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 14 Sep 2012
At a glance
- Drugs Celecoxib (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 11 Sep 2006 New trial record.